Bendamustine plus rituximab in Japanese patients with relapsed or refractory diffuse large B-cell lymphoma

This single-arm phase 3 study was conducted to confirm the results of our phase 2 study of bendamustine (B)-rituximab (R) in patients with relapsed/refractory diffuse large B cell lymphoma (rrDLBCL). The primary endpoint was overall response rate (ORR). Autologous stem cell transplantation-ineligibl...

Descripción completa

Detalles Bibliográficos
Autores principales: Murayama, Kayoko, Kiguchi, Toru, Izutsu, Koji, Kameoka, Yoshihiro, Hidaka, Michihiro, Kato, Harumi, Rai, Shinya, Kuroda, Junya, Ishizawa, Kenichi, Ichikawa, Satoshi, Ando, Kiyoshi, Ogura, Michinori, Fukushima, Koji, Terui, Yasuhito
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer Berlin Heidelberg 2022
Materias:
Original Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8993776/
https://www.ncbi.nlm.nih.gov/pubmed/35244756
http://dx.doi.org/10.1007/s00277-022-04801-2

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8993776/
https://www.ncbi.nlm.nih.gov/pubmed/35244756
http://dx.doi.org/10.1007/s00277-022-04801-2

Ejemplares similares